Passage Bio, Inc. PASG · Stock Open Passage Bio, Inc. in new tab
Passage Bio, Inc. Analysis (PASG)
Is Passage Bio, Inc. a good investment? Passage Bio, Inc. (PASG) is currently trading at 4.76 USD. Market analysts have a consensus price target of 15.50 USD. This suggests a potential upside from current levels.
Earnings Schedule: Passage Bio, Inc. is expected to release its next earnings report on Nov. 9, 2026. The market consensus estimate for Forward EPS is -10.39.
Investor FAQ
Does Passage Bio, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Passage Bio, Inc.?
Passage Bio, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 9, 2026. The company currently has a trailing EPS of -11.32.
Company Profile
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other programs for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is based in Philadelphia, Pennsylvania.
| Split Date | Split Ratio to 1 |
|---|---|
| July 14, 2025 | 1:20 |
Community Discussion